Like most, bit surprised how it has performed in the last week...

Like most, bit surprised how it has performed in the last week but I guess that's the market. I'm in the screen picking up stock as I think it's bloody cheap for a phase 3 drug that has done its first licensing deal. Neuren which might not be a perfect comparable but i believe is a good yard stick. It was trading around $250mcap at about this point. Look at BOT, thats capped around 200mc and that essentially just a deodorant

Clearly, mercer is selling in the market which is frustrating, I wonder if they will convert the other 2m con notes (39m shares) or hold them until the price fixes itself. Can't see anyone converting $0.125 options until the price is above $0.15 so i think $0.12-13 will be the floor.Bit of churning around these levels will be good for the stock in the long run, better to get out the flippers now before phase 3 results.